<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287844</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A00273-50</org_study_id>
    <nct_id>NCT02287844</nct_id>
  </id_info>
  <brief_title>Prebiotics Change Microflora and Decrease LPS</brief_title>
  <acronym>PIB</acronym>
  <official_title>Xylo-oligosaccharide (XOS) in Combination With Inulin Modulates Both the Intestinal Environment and Immune Status in Healthy Subjects, While XOS Alone Only Shows Prebiotic Properties</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur de Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Polytechnique LaSalle Beauvais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur de Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study was to establish the prebiotic effect of a new
      xylo-oligosaccharides (XOS) and of an inulin-and-XOS mixture (INU-XOS) and to determine their
      effect on endotoxaemia (lipopolysaccharides (LPS)) and immune parameters. In this randomized,
      parallel, placebo-controlled, double-blind study, sixty healthy volunteers were randomly
      assigned to three groups, receiving either 5 g XOS, INU-XOS (3 g inulin +1 g XOS) or an
      equivalent weight of wheat maltodextrins (placebo) during 4 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study followed a randomized, parallel placebo-controlled double-blind design.

      A semi-quantitative dietary survey was performed at enrollment in order to assess the usual
      dietary fiber intake in order to select the target population consuming 13 to 18 g/day. The
      volunteers were instructed to follow dietary guidelines to maintain their fiber intake during
      a two-week stabilization phase and then throughout the intervention.

      As all volunteers were living on-site and taking all meals at the Institut Polytechnique
      LaSalle Beauvais cafeteria, the content of each meal could be closely controlled during the
      week. A 3-day dietary survey was performed at the end of the stabilization period and
      repeated at the end of the intervention in order to assess the stability of the diet.

      The 60 volunteers were randomly assigned to one of three groups and received daily the
      intervention for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the intestinal bifidobacterium at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Dosage by count in the feces by Reverse transcription polymerase chain reaction (RT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the intestinal bifidobacterium at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Dosage by count in the feces by Reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in the intestinal bifidobacterium at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Dosage by count in the feces by Reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total microbiota and composition in the feces at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Total bacterial count and specific bacterial profile analyzed by quantitative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total microbiota and composition in the feces at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total bacterial count and specific bacterial profile analyzed by quantitative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in total microbiota and composition in the feces at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Total bacterial count and specific bacterial profile analyzed by quantitative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of short-chain fatty acids (C2, C3, C4) in the feces at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Acetic acid (C2), propionic acid (C3) and butyric acid (C4) extracted and measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of short-chain fatty acids (C2, C3, C4) in the feces at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Acetic acid (C2), propionic acid (C3) and butyric acid (C4) extracted and measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks of short-chain fatty acids (C2, C3, C4) in the feces at 4 weeks</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Acetic acid (C2), propionic acid (C3) and butyric acid (C4) extracted and measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the alpha-glucosidase and beta-glucuronidase activities in the feces at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the alpha-glucosidase and beta-glucuronidase activities in the feces at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in the alpha-glucosidase and beta-glucuronidase activities in the feces at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the phenol and p-Cresol in the feces at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the phenol and p-Cresol in the feces at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in the phenol and p-Cresol in the feces at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the faecal pH and dry matter at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the faecal pH and dry matter at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in the faecal pH and dry matter at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in secretory Immunoglobulin A (IgA) at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measured with s-IgA ELISA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in secretory Immunoglobulin A (IgA) at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured with s-IgA ELISA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in secretory Immunoglobulin A (IgA) at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Measured with s-IgA ELISA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cytokines at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Tumor Necrosis Factor (TNF)-alpha and Interleukine(IL)-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cytokines at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Tumor Necrosis Factor (TNF)-alpha and Interleukine(IL)-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in cytokines at 4 weeks</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Tumor Necrosis Factor (TNF)-alpha and Interleukine(IL)-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in dietary intakes at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Data extracted from a 3-day food diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in dietary intakes at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Data extracted from a 3-day food diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in dietary intakes at 4 weeks</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Data extracted from a 3-day food diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of circulating lipopolysaccharides (LPS) at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measured in plasma sample using the limulus amebocyle lysate chromogenic endpoint assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of circulating lipopolysaccharides (LPS) at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured in plasma sample using the limulus amebocyle lysate chromogenic endpoint assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks of circulating lipopolysaccharides (LPS) at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Measured in plasma sample using the limulus amebocyle lysate chromogenic endpoint assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the subjects' tolerance to the test products at 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Flatulence, bloating, rumbling, cramps, nausea, stool consistency on a Visual Analog Scale (10 cm).Stool frequency (stool per day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the subjects' tolerance to the test products at 2 weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Flatulence, bloating, rumbling, cramps, nausea, stool consistency on a Visual Analog Scale (10 cm). Stool frequency (stool per day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 2 weeks in the subjects' tolerance to the test products at 4 weeks.</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
    <description>Flatulence, bloating, rumbling, cramps, nausea, stool consistency on a Visual Analog Scale (10 cm). Stool frequency (stool per day).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Selection (at least 2 weeks before Baseline) in Weight, Height, BMI, Blood pressure, Heart rate at 4 weeks</measure>
    <time_frame>4weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Selection (at least 2 weeks before Baseline) in Weight, Height, BMI, Blood pressure, Heart rate at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from 2 weeks in Weight, Height, BMI, Blood pressure, Heart rate at 4 weeks</measure>
    <time_frame>Between 2 and 4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Prebiotics Effect</condition>
  <arm_group>
    <arm_group_label>XOS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INU-XOS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>XOS</intervention_name>
    <description>5 g of XOS everyday for 4 weeks.</description>
    <arm_group_label>XOS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>INU-XOS</intervention_name>
    <description>1 g of XOS and 3 g of inulin everyday for 4 weeks.</description>
    <arm_group_label>INU-XOS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6.64 g of maltodextrins everyday for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable weight (+/- 3 kg) for the last 3 months

          -  Body Mass Index (BMI) between 18.5 and 27 kg/mÂ²

          -  Consuming between 13 and 18 g of dietary fiber a day

          -  Student on campus at the Institut Polytechnique LaSalle Beauvais

          -  Informed consent form signed

          -  Able to follow the requirement of the study

          -  Have a social security

        Exclusion Criteria:

          -  Has a serious pathology

          -  Has a gastrointestinal, vesicular or pancreatic disease

          -  Took an antibiotic or a laxative treatment in the last 6 months

          -  Surgery of the gastrointestinal tract in the last 12 months

          -  Orange juice intolerance

          -  Chronic or recurring diarrhea, constipation or abdominal pain

          -  Taking drugs known to have an effect on the gastrointestinal, pancreatic and vesicular
             function

          -  Recent gastroenteritis or foodborne illness

          -  Diabetes

          -  Consuming regularly of probiotics- or prebiotics-enriched products in the last month

          -  Drinking more than 3 glasses of alcohol a day

          -  Is deprived of liberty

          -  Is under judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Polytechnique LaSalle Beauvais</name>
      <address>
        <city>Beauvais</city>
        <state>Oise</state>
        <zip>60000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Pasteur de Lille</investigator_affiliation>
    <investigator_full_name>Jean-Michel Lecerf</investigator_full_name>
    <investigator_title>MD, Nutritionist</investigator_title>
  </responsible_party>
  <keyword>Xylo-oligosaccharides</keyword>
  <keyword>Immunonutrition</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Lipopolysaccharides</keyword>
  <keyword>Cytokines</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

